Glaxo Smith Kline's total sales in the second quarter were £8.4 billion
On July 28, GlaxoSmithKline released its second quarter results report. Total sales in the second quarter were 8.4 billion pounds, of which specialist drug sales were 3.8 billion pounds, a year-on-year increase of 14%; vaccine sales were 2.3 billion pounds, a year-on-year increase of 8%; general drug sales were 2.3 billion pounds, a year-on-year decrease of 9%. Core operating profit in the second quarter was 2.8 billion pounds, and core earnings per share were 50.5 pence. GlaxoSmithKline expects full-year sales in 2026 to grow by 3%-5%, core operating profits to grow by 7%-9%, and core U.S. stock earnings to grow by 7%-9%.
On July 28, GlaxoSmithKline released its second quarter results report. Total sales in the second quarter were 8.4 billion pounds, of which specialist drug sales were 3.8 billion pounds, a year-on-year increase of 14%; vaccine sales were 2.3 billion pounds, a year-on-year increase of 8%; general drug sales were 2.3 billion pounds, a year-on-year decrease of 9%. Core operating profit in the second quarter was 2.8 billion pounds, and core earnings per share were 50.5 pence. GlaxoSmithKline expects full-year sales in 2026 to grow by 3%-5%, core operating profits to grow by 7%-9%, and core U.S. stock earnings to grow by 7%-9%.